An Open-Label, Multicenter Study of the Effects of Remission Maintenance Therapy with Ceplene® (Histamine Dihydrochloride), Given in Conjunction with Low-Dose Interleukin-2 (IL-2, Proleukin?), on Immune Response and Minimal Residual Disease (MRD) in Adult Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)

EpiCept Corporation0 个研究点目标入组 84 人开始时间: 2009年11月27日最近更新: 2021年12月13日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 84

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•AML patients in CR1 who have been cytogenetically well-characterized (using molecular cytogenetic techniques, eg, RQ-PCR) at diagnosis. Patients may be considered eligible if they have not had this assessment performed at diagnosis provided a viable diagnostic bone marrow sample is available on which this testing may be performed.
•Characterization of leukemia immunophenotypic fingerprint at diagnosis using MFC techniques.
•Bone marrow examination confirming CR (defined as less than 5% blasts in a normocellular bone marrow).
•Eighteen years of age or older.
•Patients have received any form of induction and consolidation therapy as per standard practice at the institution, including autologous stem cell transplantation (ASCT).
•Within 6 weeks following the date of the last dose of consolidation or conditioning chemotherapy for AML, or following ASCT.
•Platelet count recovered after chemotherapy to =75 x 109/L, and Partial Thromboplastin Time (PTT) within normal limits.
•WBC =1.5 x 109/L and LFTs (to include SGPT [ALAT] or SGOT [AST] and bilirubin) should not exceed twice the upper limit of normal.
•Serum creatinine less than or equal to 1.5 times the upper normal limit.
•Able to function without significant decrease in daily activities (WHO Performance Status 0 - 1 or Karnofsky =70, refer to Appendix 1).
•Life expectancy of more than three months and able to undergo routine outpatient evaluations for efficacy, safety, and/or compliance.
•Women of childbearing potential must be practicing barrier or oral contraception, for the duration of the treatment, or documented as surgically sterile or one year post-menopausal.
•If female, be non-nursing, non-pregnant and have a negative pregnancy test within two weeks of starting study drug.
•The patient must be informed of the investigational nature of the study and written informed consent obtained.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Patients who have undergone or are planned for allogeneic stem cell transplantation.
•Patients with M3 as an AML subtype.
•Class III or IV cardiac disease, hypotension or severe hypertension, vasomotor instability, serious or uncontrolled cardiac dysrhythmias (including ventricular arrhythmias) at any time, acute myocardial infarction within the past 12 months, active uncontrolled angina pectoris or symptomatic arteriosclerotic blood vessel disease.
•Other active malignancies except in situ carcinoma of the cervix, localized squamous or basal cell carcinoma of the skin.
•Serious concurrent or recent non-malignant medical conditions which, in the opinion of the Investigator, makes the patient unsuitable for participation in this study.
•History of seizures, central nervous system disorders, stroke within the last 12 months, or psychiatric disability thought to be clinically significant in the opinion of the Investigator and adversely affecting compliance to protocol.
•Patients unable to undergo repeat treatments, clinical evaluations and other diagnostic procedures required by the protocol.
•Prior history of autoimmune disease (including but not limited to systemic lupus, inflammatory bowel disease, and psoriasis).
•Patients with active peptic or esophageal ulcer disease or with past peptic ulcer or esophageal disease with a history or bleeding.
•Patients requiring active treatment for hypotension.
•Medical, sociologic, or psychological impediment to probable compliance with the protocol.
•Patients continuing systemic treatment with clonidine, steroids, and/or H2 receptor blocking agents.
•Patients with a history of hypersensitivity to histamine or histamine products, severe allergies to food or contrast media requiring treatment within the last five years.

研究者

发起方

EpiCept Corporation

相似试验

进行中（未招募）

不适用

A Study to Assess the Effects of Remission Maintenance Therapy with Ceplene®, Given with Low-Dose Interleukin-2 (IL-2, Proleukin®), on Immune Response and Minimal Residual Disease (MRD) in Adult Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)Acute Myeloid Leukemia in First Complete Remission (CR1)MedDRA version: 16.1Level: LLTClassification code 10000887Term: Acute myeloid leukemia in remissionSystem Organ Class: 100000004864

EUCTR2009-012083-14-SEMEDA Pharma GmbH & Co. KG150

进行中（未招募）

1 期

EUCTR2009-012083-14-BEMeda Pharma GmbH & Co. KG150

进行中（未招募）

1 期

EUCTR2009-012083-14-GBMEDA Pharma GmbH &Co. KG84

进行中（未招募）

不适用

An Open-Label Multicenter Study of the Effects of Remission Maintenance Therapy with Ceplene (Histamine Dihydrochloride) Given in Conjunction with Low-Dose Interleukin-2 (IL-2 Proleukin) on Immune Response and Minimal Residual Disease (MRD) in Adult Patients with Acute Myeloid Leukemia in First Complete Remission (CR1) - EPC2008-02 Ceplene and IL-2 in AMPatients affected by Acute Myeloid LeukemiaMedDRA version: 12.1Level: LLTClassification code 10000887Term: Acute myeloid leukemia in remission

EUCTR2009-012083-14-ITEpiCept Corporation150

进行中（未招募）

1 期

A Study of Superoxide Dismutase Mimetic GC4419 for the reduction of Severe Oral Mucositis (SOM) in patients with head and neck cancerSevere Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck CancerMedDRA version: 20.0Level: LLTClassification code 10028130Term: Mucositis oralSystem Organ Class: 100000004856

EUCTR2019-002745-38-PLGalera Therapeutics, Inc.70